ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
Registry-linked trialOpen access · bronzeAbstract readConsensus StatementHistorical Article
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05681416 (Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer), which is not on this map. Cited by 150 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 5 pooled it
33.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer
Who cites it
150 citing papers in PubMed, 5 syntheses or guidelines pooled it, 275 citations in OpenAlex.
- [Hereditary genetic testing and its application in the diagnosis, treatment, and prevention of breast cancer].Magyar onkologia · 2025Guideline
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response.International journal of molecular sciences · 2025Pooled it
- Application and optimization of prostate-specific antigen screening strategy in the diagnosis of prostate cancer: a systematic review.Frontiers in oncology · 2023Pooled it
- Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment.The oncologist · 2021Pooled it
- SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Guideline
- TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.JCO precision oncology · 2024Trial
- Streamlined Genetic Education and Cascade Testing in Men from Hereditary Breast Ovarian Cancer Families: A Randomized Trial.Public health genomics · 2024Trial
- Bridging the implementation gap in hereditary cancer care for prostate cancer: a narrative review and Japanese environmental scan.International journal of clinical oncology · 2026Review
- Africa's emerging role in precision oncology: translational insights from the harnessing functional genomics in cancer research conference, Windhoek, 23-26 September 2025.BMC proceedings · 2026Article
- Understanding the utilization of genetic counseling and testing among patients with prostate cancer.The Canadian journal of urology · 2026Article
- Implementation of Genetic Testing in Prostate Cancer: A Real-World Survey of Outpatient Urologists in Germany (PRO-GEN).Cancers · 2026Article
- Knowledge and attitudes toward prostate cancer germline genetic testing among Hispanic males.Prostate cancer and prostatic diseases · 2026Article
- Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients.Prostate cancer and prostatic diseases · 2026Article
- Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry.European urology · 2026Article
- Article
- Genetic Testing and Imaging in Men with Familial History or Genetic Predisposition of Prostate Cancer-Introducing the Prospective "ProFam-Risk" Study.European urology open science · 2026Article
- Delphi panel consensus on genetic testing for prostate cancer in Australia: Whom to test and how?Familial cancer · 2026Article
- SOGUG Multidisciplinary Expert Panel Consensus on Updated Diagnosis and Characterization of Prostate Cancer Patients.Current oncology (Toronto, Ont.) · 2026Review
- Hereditary Prostate Cancer Risk Management: An Evidence-Based Summary to Inform Nursing Practice.Journal of multidisciplinary healthcare · 2026Review
- DNA damage repair gene defects combined predict the efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: a retrospective cohort study.Frontiers in genetics · 2026Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
92 authors at 20 institutions in 3 countries.
Veda N GiriDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Karen E KnudsenDepartment of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
William K KellyDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Heather H ChengDepartment of Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Division of Clinical Research, Seattle, WA.
Kathleen A CooneyDuke University School of Medicine and Duke Cancer Institute, Durham, NC.
Michael S CooksonUniversity of Oklahoma College of Medicine, Norman, OK.
William DahutGenitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Scott WeissmanNational Society of Genetic Counselors, Chicago, IL.
Howard R SouleProstate Cancer Foundation, Santa Monica, CA.
Daniel P PetrylakYale Cancer Center, New Haven, CT.
Adam P DickerDepartment of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Saud H AlDubayanDana-Farber Cancer Institute, Boston, MA.
Amanda E TolandDepartment of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Colin C PritchardDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Curtis A PettawayThe University of Texas MD Anderson Cancer Center, Houston, TX.
Mary B DalyFox Chase Cancer Center, Philadelphia, PA.
James L MohlerRoswell Park Comprehensive Cancer Center, Buffalo, NY.
J Kellogg ParsonsMoores UC San Diego Comprehensive Cancer Center, San Diego, CA.
Peter R CarrollDepartment of Urology, University of California, San Francisco, San Francisco, CA.
Robert PilarskiJames Comprehensive Cancer Center and Department of Internal Medicine, The Ohio State University, Columbus, OH.
Amie BlancoUniversity of California, San Francisco, Cancer Genetics and Prevention Program, San Francisco, CA.
Ashley WoodsonThe University of Texas MD Anderson Cancer Center, Houston, TX.
Alanna RahmCenter for Health Research, Genomic Medicine Institute, Geisinger, Danville, PA.
Mary-Ellen TaplinDana-Farber Cancer Institute, Boston, MA.
Thomas J PolascikDuke University Medical Center, Durham, NC.
Brian T HelfandNorth Shore University Health System, Evanston, IL.
Colette HyattSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Alicia K MorgansNorthwestern University, Chicago, IL.
Felix FengDepartments of Radiation Oncology, Urology, and Medicine, University of California, San Francisco, San Francisco, CA.
Michael MullaneAdvocate Aurora Health, Milwaukee, WI.
Jacqueline PowersUniversity of Pennsylvania, Basser Center for BRCA, Philadelphia, PA.
Raoul ConcepcionIntegra Connect, West Palm Beach, FL.
Daniel W LinUniversity of Washington, Seattle, WA.
Richard WenderAmerican Cancer Society, Atlanta, GA.
James Ryan MarkDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Anthony CostelloUrology at Royal Melbourne Hospital, North Melbourne, VIC, Australia.
Arthur L BurnettJohns Hopkins Medical Institutions, Baltimore, MD.
Oliver SartorTulane University, New Orleans, LA.
William B IsaacsBrady Urological Institute, Johns Hopkins Medicine, Baltimore, MD.
Jianfeng XuNorth Shore University Health System, Evanston, IL.
Jeffrey WeitzelCity of Hope Comprehensive Cancer Center, Duarte, CA.
Gerald L AndrioleWashington University School of Medicine, St Louis, MO.
Himisha BeltranDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Alberto BrigantiUnit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Lindsey ByrneThe Ohio State University, Columbus, OH.
Anne CalvaresiDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Thenappan ChandrasekarDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
David Y T ChenFox Chase Cancer Center, Philadelphia, PA.
Robert B DenDepartment of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Albert DobiHenry Jackson Foundation for the Advancement of Military Medicine, Center for Prostate Disease Research, Department of Surgery, Uniformed Services University and the Walter Reed National Military Medical Center, Bethesda, MD.
E David CrawfordUniversity of California, San Diego, La Jolla, CA.
James EasthamMemorial Sloan Kettering Cancer Center, New York, NY.
Scott EggenerUniversity of Chicago, Chicago, IL.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Marc GarnickBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Patrick T GomellaNational Cancer Institute, National Institutes of Health, Bethesda, MD.
Nathan HandleyDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Mark D HurwitzDepartment of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Joseph IzesDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
R Jeffrey KarnesMayo Clinic, Rochester, MN.
Costas LallasDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Lucia LanguinoDepartment of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Stacy LoebDepartment of Urology and Population Health, New York University and Manhattan Veterans Affairs, New York, NY.
Ana Maria LopezDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Kevin R LoughlinHarvard Medical School, Boston, MA.
Grace Lu-YaoDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
S Bruce MalkowiczUniversity of Pennsylvania, Philadelphia, PA.
Mark MannDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Patrick MilleDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Martin M MinerBrown University, Providence, RI.
Todd MorganUniversity of Michigan, Ann Arbor, MI.
Jose MorenoMidlantic Urology, Phoenixville, PA.
Lorelei MucciDepartment of Epidemiology, Harvard TH Chan School of Public Health, Boston MA.
Ronald E MyersDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Sarah M NielsenUniversity of Chicago, Chicago, IL.
Brock O'NeilUniversity of Utah, Huntsman Cancer Institute, Salt Lake City, UT.
Wayne PinoverAbington-Jefferson Hospital, Abington, PA.
Peter PintoNational Cancer Institute, National Institutes of Health, Bethesda, MD.
Wendy PoageProstate Conditions Education Council, Elizabeth, CO.
Ganesh V RajUniversity of Texas Southwestern Medical Center at Dallas, Dallas, TX.
Timothy R RebbeckDepartment of Epidemiology, Harvard TH Chan School of Public Health, Boston MA.
Charles RyanUniversity of Minnesota and Masonic Cancer Center, Madison, WI.
Howard SandlerCedars-Sinai Medical Center, Los Angeles, CA.
Matthew SchiewerDepartment of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
E Michael D ScottProstate Cancer International, Virginia Beach, VA.
Brittany SzymaniakNorthwestern Medical Group, Urology Department, Chicago, IL.
William TesterDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Edouard J TrabulsiDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Neha VapiwalaUniversity of Pennsylvania, Philadelphia, PA.
Evan Y YuUniversity of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.
Charnita Zeigler-JohnsonDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Leonard G GomellaDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Sidney Kimmel Cancer Center · USThomas Jefferson University · USDana-Farber Cancer Institute · USHarvard University · USUniversity of Washington · USThe Ohio State University · USUniversity of California, San Francisco · USUniversity of Pennsylvania · USFox Chase Cancer Center · USNational Cancer Institute · USNorthShore University HealthSystem · USProstate Cancer Foundation · USThe University of Texas MD Anderson Cancer Center · USUniversity of Chicago · USAmerican Cancer Society · USAurora Health Care · USBrown University · USCedars-Sinai Medical Center · USCity of Hope · USDuke Medical Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MVIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MX-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8MRole of Runx2 in prostate tumorigenesis and metastasisP01CA140043 · NCI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2010 to 2021
$12.2MThe Evaluation of Novel Therapeutics for Genitourinary MalignanciesZIASC010098 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI DAHUT, WILLIAM L. · 2009 to 2022
$7.6MIntegrin-mediated mechanisms of prostate cancer progressionR01CA224769 · NCI · THOMAS JEFFERSON UNIVERSITY · PI LANGUINO, LUCIA R. · 2018 to 2022
$2.0MNCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA140043NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA224769
Abstract
purposeGermline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services.
methodsA multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider).
resultsLarge germline panels and somatic testing were recommended for metastatic PCA. Reflex testing-initial testing of priority genes followed by expanded testing-was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included
conclusionThis multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.
Indexed as
Genetic TestingGerm-Line MutationHistory, 20th CenturyHumansMaleProstatic Neoplasms
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05681416ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.